The antibiotic crisis must be viewed through a different lens.
Academic rigor, journalistic flair
Articles on Drug development
Displaying 1 - 20 of 53 articles
Box jellyfish stings are excruciating and occasionally deadly. We have identified a common, cheap drug that is already on the market and which could be a treatment candidate with further development.
Techniques from topology can help us understand DNA and improve drug development.
Developing drugs is typically the domain of large pharmaceutical companies. But here is an example of drug development for a rare pediatric brain cancer that was done in a university setting.
Drug trials should include people with more than one disease.
Nature doesn't always make the things we need so three Nobel Prize winners figured out how to fast-track evolution in the lab to create medicines, biofuels and industrial chemicals for modern life.
Trials for new Alzheimer's drugs have been failing a lot, lately. But it may be premature to abandon these drugs altogether.
Alzheimer's drug development tends to focus on protein aggregates in the brain. Perhaps that's why they've all failed.
Researchers who've created a kidney-on-a-chip explain why these kinds of devices are an improvement over traditional ways to test new drugs.
Thousands of animals are used for heart drug tests each year – but research shows that in silico developments are more accurate.
Medicinal chemists are tweaking a natural molecule that can be a deadly poison – a modified version might work as a nonhormonal male contraceptive.
Only around 10% of new drugs in development make it onto the market. A drug needs to go through animal trials, and then four phases of human trials to be deemed suitable for use in patients.
A randomised controlled trial is the best way to compare a new treatment with the standard treatment. And randomising trial participants is a core feature of the experiment.
3D bioprinting of living cells and materials may contribute to faster and cheaper ways to create effective new drugs - and even reduce animal testing.
Researchers are finding medical uses for some molecules in certain street drugs, but it's important to call the drugs by their real names. Here’s why that's important.
Australia has never been short of inventors, scientists aren't always at home in the ruthless world of commerce. But if they can be given a helping hand, it could help the entire economy.
News reports this week hailing a breakthrough in Alzheimer's research, saying a vaccine for the disease is a few years away, have raised hopes for many. But let's take a step back from the headlines.
Human guinea pigs? On the occasion of Rennes drama, an explanation of what the drug trials in France and how they are controlled.
Many venoms contain bioactive components that are so stable to the body's enzymes and selective of their biological target that they're increasingly being used as novel research tools.
Thalidomide was developed in an era of widespread enthusiasm – but little critical attention – for pharmaceutical therapies.
Top contributors
-
Prof. Institute for Molecular Bioscience, The University of Queensland
-
Professor of Neuroscience, Lancaster University
-
Associate Professor of History, University of Wollongong
-
Associate professor, UNSW
-
Biostatistician, University of Melbourne
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Associate Professor of Biostatistics, Murdoch Children's Research Institute
-
Lyn Gilbert is a Friend of The Conversation.
Clinical Professor in Medicine and Infectious Diseases, University of Sydney
-
Professor of Bioethics & Medicine, Sydney Health Ethics, University of Sydney
-
Emeritus Professor of Medical Ethics, The University of Queensland
-
Associate professor, University of Melbourne
-
Adjunct Fellow, School of Law & School of Medicine, Western Sydney University
-
Executive General Manager Commercialisation and Research Contracts, Baker Heart and Diabetes Institute
-
Senior Fellow at Research for Social Change, University of Wollongong
-
Distinguished Writer In Residence, Arthur Carter Journalism Institute, New York University
